RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 SC Ibalizumab Warrants Further Study for Preventing HIV-1 Infection
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 28
SP 9
OP 10
DO 10.1177/155989771428004
UL http://mdc.sagepub.com/content/14/28/9.abstract
AB Among the strategies being explored to prevent infection with human immunodeficiency virus type 1 is ibalizumab, a humanized monoclonal antibody that binds to CD4 domain 2 and blocks the entry of HIV-1 into CD4-positive T cells. This article discusses the Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (TMB-108) [NCT01292174] results of a study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous injections of ibalizumab.